XSHG
603676
Market cap555mUSD
Jul 10, Last price
8.76CNY
1D
1.15%
1Q
-17.82%
IPO
0.00%
Name
Tibet Weixinkang Medicine Co Ltd
Chart & Performance
P/E
16.37
P/S
3.36
EPS
0.54
Div Yield, %
3.78%
Shrs. gr., 5y
0.66%
Rev. gr., 5y
9.68%
Revenues
1.14b
-12.65%
Net income
233m
-5.41%
CFO
186m
-50.23%
Dividend
Nov 26, 20250.147 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tibet Weixinkang Medicine Co., Ltd., a pharmaceutical enterprise headquartered in Lhasa, China, is dedicated to the entire lifecycle of medicinal products within the country, encompassing their research and development, manufacturing, and sales. The company's diverse range of offerings includes specialized vitamins for parenteral nutrition, electrolyte solutions, intravenous iron preparations, antibiotic medications, and therapies designed for digestive system and liver conditions. Among its specific injectable products are multivitamins, potassium magnesium aspartate, iron sucrose, and potassium aspartate. Established in 2006, the firm operated under the name Weixinkang Medicine Youxian Gongsi until its rebranding to Tibet Weixinkang Medicine Co., Ltd. occurred in 2015.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||